Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
about
Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition.Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma modelClinical Development of the E75 Vaccine in Breast CancerT cell receptor-like recognition of tumor in vivo by synthetic antibody fragmentPoor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptideSerine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patientsCleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patientsIdentification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarrayHuman Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune responseIdentification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells.Tumor antigens and tumor vaccines: peptides as immunogens.Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.Human tumor antigens for cancer vaccine development.Role of HER2 gene overexpression in breast carcinoma.Anti-HER2 vaccines: new prospects for breast cancer therapyIdentification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity.Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.Advances in the study of HLA-restricted epitope vaccines.Gene therapy: development of immunostimulatory treatments for cancer.Recent advances in the development of breast cancer vaccines.Recent advances in the treatment of epithelial ovarian cancer.Cancer genetics and tumor antigens: time for a combined view?Progress in the development of immunotherapy for the treatment of patients with cancer.Immunotherapy for melanoma.Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen.Immunotherapy for ovarian cancer: what's next?Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas.Synthetic peptides as cancer vaccines.The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Whole tumor antigen vaccines.Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogeneThe HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors.A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.Peptide-based vaccines for cancer immunotherapy.Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysateImproved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
P2860
Q24801995-EAC0E28D-7E14-41DD-AD8E-BB9764EF4961Q24805875-E89CEE86-A890-4B13-9806-4BE713A2B2A4Q26745440-73F7DB44-DA59-4E6D-AF8E-9FEC264AD7FEQ27322455-2DD22C61-54EF-4B53-95C2-0DAAE4874816Q27620636-2A699F68-79BA-4A14-BD7E-EB42EC77C436Q28202640-13F097D1-8FAE-4D0B-80BA-957BA7463811Q28216625-09779112-9315-4931-91CA-659E203E095DQ28235811-385D2FE7-AB86-42BF-BA29-174FD9BEA8C3Q28251022-B566A864-4255-4D80-B624-AE7AB28BC89EQ30442906-34DA449D-0E75-488D-9F93-3E21A6C43CCCQ30469630-D226B751-08C7-41BF-90FF-7B4409BAD031Q33357295-C91F09D1-C6B3-4C8C-AE53-76C2F46D8941Q33724878-25B7C2C4-BECF-49BB-B665-22B661298A9FQ33776127-2A0E648E-430E-493C-A778-6296EBFCE5A4Q33810080-B060311A-67FD-4ADF-932C-575ECDF349E6Q34105959-607A9325-9390-43EE-A4EC-89BB6F68538DQ34111830-A5379405-F4E1-4F8E-9111-231C0A408813Q34155839-FD445F31-CD8D-40BD-AF37-BDB24E807B9CQ34170130-74D06A7A-135B-4004-94AB-907B92C3C26CQ34187915-2306DEE0-3BDE-4DC3-BE52-210C987480ADQ34379303-96406E7C-AAB5-48F1-9A20-6F81FB171577Q34481727-467AB85F-AFE9-4610-849D-2838903C7BBBQ34495646-9C6D5D30-AA29-4E5F-8BA7-1B37170CF0B0Q34570245-7ADCA2C8-5B00-4EE9-8D47-578A45939589Q34573035-67DB570D-04D6-425F-A63A-0EA058DC3EB2Q34721861-061540CE-2C2E-4814-8164-D8FC874A2027Q34743514-2869A8AD-20BB-4764-B7DA-6C7F0CFF4A5EQ34914935-3A5E5B9F-C346-4E4E-9BF9-4451BF06133FQ34972916-2E83B1E6-A70C-4812-A0F1-BFED5CF24CDBQ35058213-E23A630F-1FD9-4DE5-B667-FB44E46FF5BDQ35058235-B6F20924-0E7D-499D-8B4E-4C6D55E14A6EQ35149885-66E5569E-C81E-41EE-915F-BBC631CB8BE6Q35181440-5C34357C-8AE1-454A-B30C-F6508C0E0CFCQ35182373-F97DAB47-FDE0-40A5-83CF-7C7AB69A55CDQ35232992-D414F8CD-2854-4458-9336-FAABB6BCCFD0Q35621559-05AAC52A-1E00-4603-BA0C-BBD94C526ED9Q35681508-14860B80-EB67-4985-A636-594DA6A56392Q35768996-C76C6DC1-18E0-4341-BF07-DE4E02C2B7F8Q35789363-7F9BB420-24DA-4E8E-93E9-880C87820E3CQ36011425-FD6511C3-2689-4BC9-AE70-0192296FB164
P2860
Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Identification of an immunodom ...... cytotoxic T lymphocyte lines.
@ast
Identification of an immunodom ...... cytotoxic T lymphocyte lines.
@en
type
label
Identification of an immunodom ...... cytotoxic T lymphocyte lines.
@ast
Identification of an immunodom ...... cytotoxic T lymphocyte lines.
@en
prefLabel
Identification of an immunodom ...... cytotoxic T lymphocyte lines.
@ast
Identification of an immunodom ...... cytotoxic T lymphocyte lines.
@en
P2093
P2860
P356
P1476
Identification of an immunodom ...... cytotoxic T lymphocyte lines.
@en
P2093
C G Ioannides
J T Wharton
T L Blevins
P2860
P304
P356
10.1084/JEM.181.6.2109
P407
P577
1995-06-01T00:00:00Z